Delivering genetic education and genetic counseling for rare diseases in rural Brazil

Brazil is the largest country in Latin America, with an ethnically diverse, Portuguese-speaking and predominantly Roman Catholic population of some 194 million. Universal health care is provided under the Federal Unified Health System (Sistema Único de Saúde) but, as in many other middle and low income countries, access to medical genetics services is limited in rural and remote regions of the country. Since there is no formally recognized Genetic Counseling profession, genetic counseling is provided by physicians, trained either in medical genetics or a related clinical discipline. A comprehensive medical genetics program has been established in Monte Santo, an inland rural community located in the state of Bahia in Northeast Brazil, with high prevalences of a number of autosomal recessive genetic disorders, including non-syndromic deafness, phenyketonuria, congenital hypothyroidism and mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). Genetic education, counseling and treatment are locally provided, with a neonatal screening program for MPSVI currently under trial

Factors associated with father involvement in infant care

OBJECTIVE: To identify factors associated with the lack of active father involvement in infant care at four months of age. METHODS: Cross-sectional study involving families of 153 infants at four months of age, interviewed in their homes by two family therapists. In addition to father involvement in infant care, sociodemographic, parental mental health (using the Self Report Questionnaire-20 scale and Diagnostic and Statistical Manual of Mental Disorders-IV criteria assessment) and quality of couple relationship characteristics (using the Assessment of Relational Functioning from Diagnostic and Statistical Manual of Mental Disorders-IV) were analyzed. Poisson regression was employed to assess the association between lack of father involvement in child care and the variables selected. Prevalence ratio was used to estimate the magnitude of associations. RESULTS: Fathers of 13% of infants had no contact with their children. Among families whose parents lived together (78% of all), 33% of the fathers reported not actively participating in their children's care. Problematic couple relationship and mother as a housewife were associated with lack of father involvement in infant care. CONCLUSIONS: High prevalence of families whose father is not actively involved with infant care, especially when couple relationship is problematic and the mother does not have a paid job.OBJETIVO: Identificar factores asociados a la falta del envolvimiento activo del papá en los cuidados de niños a los cuatro meses. MÉTODOS: Se realizó estudio transversal involucrando familias de 153 niños de cuatro meses de edad, y se entrevistaron en sus casas por dos terapeutas de familias en Porto Alegre (Sureste de Brasil), 1998-2000. Además de involucrar al padre en los cuidados del lactante se examinaron características sociodemográficas, salud mental de los papás (utilizando la escala Self Report Questionnaire-20 y evaluación con los criterios del Diagnostic and Statistical Manual of Mental Disorders-IV) y calidad de la relación de pareja (usando la escala GlobalAssesment of Relational Functioning del Diagnostic and Statistical Manual of Mental Disorders-IV). Se utilizó la regresión de Poisson para evaluar la asociación entre falta de envolvimiento del papá en los cuidados del hijo y variables seleccionadas. La magnitud de las asociaciones fue estimada por la razón de prevalencia. RESULTADOS: Los papás de 13% de los lactantes no tenían contacto alguno con sus hijos. Entre las familias en que los papás cohabitaban (78% del total), 33% de ellos expresaron no participar activamente en los cuidados de sus hijos. La relación de pareja problemática y la mamá ser "del hogar" se mostraron asociados a la falta de envolvimiento de los papás en los cuidados del hijo. CONCLUSIONES: Es alta la prevalencia de familias en las cuales el papá no se involucra de manera activa en el cuidado de su hijo, ocurriendo en especial cuando la relación de pareja es problemática y la mamá no tiene trabajo remunerado.OBJETIVO: Identificar fatores associados à falta de envolvimento ativo do pai nos cuidados de crianças aos quatro meses. MÉTODOS: Estudo transversal envolvendo famílias de 153 crianças aos quatro meses de vida, entrevistadas em suas casas por dois terapeutas de famílias. Além do envolvimento do pai nos cuidados do lactente foram examinadas características sociodemográficas, saúde mental dos pais (utilizando a escala Self Report Questionnaire-20 e avaliação com os critérios do Diagnostic and Statistical Manual of Mental Disorders-IV) e qualidade do relacionamento conjugal (usando a escala Global Assessment of Relational Functioning do Diagnostic and Statistical Manual of Mental Disorders-IV). Utilizou-se regressão de Poisson para avaliar a associação entre falta de envolvimento do pai nos cuidados do filho e variáveis selecionadas. A magnitude das associações foi estimada pela razão de prevalências. RESULTADOS: Os pais de 13% dos lactentes não tinham qualquer contato com seus filhos. Entre as famílias em que os pais coabitavam (78% do total), 33% dos pais relataram não participar ativamente nos cuidados de seus filhos. Relação conjugal problemática e mãe ser "do lar" mostraram-se associadas à falta de envolvimento dos pais nos cuidados do filho. CONCLUSÕES: É alta a prevalência de famílias nas quais o pai não tem envolvimento ativo no cuidado de seu filho, ocorrendo em especial quando a relação conjugal é problemática e a mãe não tem trabalho remunerad

Clinical outcomes in a subpopulation of adults with Morquio A syndrome: results from a long-term extension study of elosulfase alfa

Background: This post hoc subanalysis examined outcomes in adult patients with Morquio A (mucopolysaccharidosis IVA) who received enzyme replacement therapy (ERT) with elosulfase alfa over a 120-weeks period. Patients ≥18 years of age evaluated in an open-label, long-term extension study of elosulfase alfa (modified per protocol [MPP], n = 32; intent-to-treat [ITT], n = 37; MOR-005; NCT01415427) were compared with the ≥18-year-old untreated population with 2-years follow-up from a Morquio A natural history study (n = 10; MorCAP; NCT00787995). The MOR-005 MPP population excluded patients who underwent orthopedic surgical procedures or were noncompliant with study protocol (defined as missing ≥20% of ERT infusions). No MorCAP patients underwent orthopedic surgical procedures during the relevant time period. Endurance was assessed by the 6-min walk test (6MWT) and 3-min stair climb test (3MSCT). Activities of daily living (ADLs) were assessed by the MPS Health Assessment Questionnaire (MPS HAQ). / Results: Least squares (LS) mean (SE) 6MWT distances increased by 34.9 (11.7) m (MPP) and 30.5 (10.8) m (ITT) by week 120; LS mean (SE) change in 3MSCT at week 120 was 6.7 (1.8) stairs/min (MPP) and 5.9 (1.7) stairs/min (ITT). MorCAP patients showed no improvement in 6MWT distance or 3MSCT over a similar period of time. Pulmonary function measures remained unchanged in both MOR-005 and MorCAP adults. All MPS HAQ domain scores improved in MOR-005 adults, whereas MorCAP adults had unchanged caregiver assistance and mobility outcomes and worsened self-care outcomes. / Conclusions: Long-term ERT in adult patients with Morquio A was associated with increased endurance and improvement in performance of ADLs. / Trial registration: Trial Registration NCT01415427. Name of registry: Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome). Registered 8 August 2011, retrospectively registered

Long-term follow-up of renal function in patients treated with migalastat for Fabry disease

The effect of migalastat on long-term renal outcomes in enzyme replacement therapy (ERT)–naive and ERT-experienced patients with Fabry disease is not well defined. An integrated posthoc analysis of the phase 3 clinical trials and open-label extension studies was conducted to evaluate long-term changes in renal function in patients with Fabry disease and amenable GLA variants who were treated with migalastat for ≥2 years during these studies. The analysis included ERT-naive (n = 36 [23 females]; mean age 45 years; mean baseline estimated glomerular filtration rate (eGFR), 91.4 mL/min/mL/1.73 m2) and ERT-experienced (n = 42 [24 females]; mean age, 50 years; mean baseline eGFR, 89.2 mL/min/1.73m2) patients with amenable variants who received migalastat 123 mg every other day for ≥2 years. The annualized rate of change from baseline to last observation in estimated glomerular filtration rate using the Chronic Kidney Disease Epidemiology Collaboration equation (eGFRCKD-EPI) was calculated by both simple linear regression and a random coefficient model. In ERT-naive patients, mean annualized rates of change from baseline in eGFRCKD-EPI were − 1.6 mL/min/1.73 m2 overall and − 1.8 mL/min/1.73 m2 and − 1.4 mL/min/1.73 m2 in male and female patients, respectively, as estimated by simple linear regression. In ERT-experienced patients, mean annualized rates of change from baseline in eGFRCKD-EPI were − 1.6 mL/min/1.73 m2 overall and − 2.6 mL/min/1.73 m2 and − 0.8 mL/min/1.73 m2 in male and female patients, respectively. Mean annualized rate of change in eGFRCKD-EPI in ERT-naive patients with the classic phenotype (defined by white blood cell alpha galactosidase A [α-Gal A] activity of <3% of normal and multiorgan system involvement) was −1.7 mL/min/1.73 m2. When calculated using the random coefficient model, which adjusted for sex, age, and baseline renal function, the annualized eGFRCKD-EPI change was minimal (mean: −0.1 and 0.1 mL/min/1.73 m2 in ERT-naive and ERT-experienced patients, respectively). In conclusion, patients with Fabry disease and amenable GLA variants receiving long-term migalastat treatment (≤8.6 years) maintained renal function irrespective of treatment status, sex, or phenotype

A 15-year perspective of the fabry outcome survey

The Fabry Outcome Survey (FOS) is an international long-term observational registry sponsored by Shire for patients diagnosed with Fabry disease who are receiving or are candidates for therapy with agalsidase alfa (agala). Established in 2001, FOS provides long-term data on agala safety/efficacy and collects data on the natural history of Fabry disease, with the aim of improving clinical management. The FOS publications have helped establish prognostic and severity scores, defined the incidence of specific disease variants and implications for clinical management, described clinical manifestations in special populations, confirmed the high prevalence of cardiac morbidity, and demonstrated correlations between ocular changes and Fabry disease severity. These FOS data represent a rich resource with utility not only for description of natural history/therapeutic effects but also for exploratory hypothesis testing and generation of tools for diagnosis/management, with the potential to improve future patient outcomes

Impact of long-term elosulfase alfa treatment on respiratory function in patients with Morquio A syndrome

OBJECTIVE: To present long-term respiratory function outcomes from an open-label, multi-center, phase 3 extension study (MOR-005) of elosulfase alfa enzyme replacement therapy (ERT) in patients with Morquio A syndrome. METHODS: In part 1 of MOR-005, patients initially randomized to ERT in the 24-week pivotal study (MOR-004) remained on their regimen (2.0 mg/kg/week or every other week); placebo patients were re-randomized to one of the two regimens. During part 2, all patients received elosulfase alfa 2.0 mg/kg/week. Respiratory function was one of the efficacy endpoints evaluated in MOR-005. Change from MOR-004 baseline to 120 weeks of treatment for the combined population was determined and compared with results from untreated patients from a Morquio A natural history study (MorCAP). RESULTS: Maximum voluntary ventilation (MVV) improved up to week 72 and then stabilized; forced vital capacity (FVC) and forced expiratory volume in 1 s (FEV1) increased continuously over 120 weeks. Mean increases in the modified per-protocol population was 9.2 % for FVC, 8.8 % for FEV1, and 6.1 % for MVV after 120 weeks. All patients ≤14 years showed respiratory improvements, presumably in part related to growth; however, these were greater in treated patients. For those >14 years, treated patients showed improvements, while deterioration occurred in untreated. Altogether, the improvements were significantly greater (P < 0.05) in treated patients. CONCLUSIONS: Long-term ERT is associated with sustained improvements in respiratory function in Morquio A. In younger patients (≤14 years), some improvement may be ascribed to growth. In older patients, other mechanisms, e.g., decreased glycosaminoglycan storage, are likely involved